Stolnicu S

Idioma: Ingles.
Referencias bibliográficas: 39
Paginas: 174-179
Archivo PDF: 344.78 Kb.

RESUMEN

El perfil de expresión de genes ha desafiado el sistema tradicional de clasificación histopatológica y ha clasificado a los carcinomas infiltrantes de la mama en cinco subgrupos distintos: carcinoma semejante a la glándula mamaria normal, luminal A, luminal B, con sobreexpresión de HER2 y carcinoma de fenotipo basal. Inicialmente, el subgrupo de carcinoma de mama de fenotipo basal se caracterizópor un patrón morfológico y un perfil inmunohistoquímico específicos (expresión de citoqueratinas de fenotipo basal, negatividad para receptores de estrógeno y de progesterona y HER-2), pero también por un resultado clínico malo. Sin embargo, más artículos recientes han mostrado que el carcinoma de mama de fenotipo basal no es un subgrupo uniforme de tumores, sino un grupo heterogéneo, que incluye tumores que pueden mostrar morfología, grado histológico, características inmunohistoquímicas y respuesta a la quimioterapia diferentes. Además, existen resultados contradictorios en la bibliografía con respecto al resultado global de los pacientes con este tipo de carcinoma de mama, probablemente debido a la falta de criterios estrictos para definir la lesión, que también pueden afectar el número de tumores publicados y reconocidos como de esta categoría. Ahora se necesitan criterios precisos para estandarizar los estudios clínicos en este grupo de tumores, que podrían curarse con diferentes estrategias terapéuticas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan, 2000. Int J Cancer 2001;94(2):153- 156.

2. Tavassoli FA. Patholohy of the breast. 2nd ed. Stamford: Appleton and Lange, 1999.

3. Moifar F. Essentials of Diagnostic Bresat Pathology, Berlin, Springer, 2007.

4. Riley RD, Abrams KR, Sutton AJ, Lambert PC, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191-1198.

5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, et al. Molecular portraits of human bresat tumors. Nature 2000;406:747-752.

6. Sorlie T, Perou CM, Tibshiranin R, Aas T, et al. Gene expression pattern of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869- 10874.

7. Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology 2008;52:108-118.

8. Moinfar F. Is basal-like carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes. Pathobiology 2008;75:119-131.

9. Laakso M, Loman N, Borg A, Isola J. Cytokeratin 5/14- positive breast cancer: true basal phenotype confined to BRCA 1 tumors. Mod Pathol 2005;18(10):1321-1328.

10. Fulford LG, Reis-Filho JS, Ryder K, Jones C, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9(1):R4.

11. Schneider BP, Winer EP, Foulkes WD, Garber J, et. al. Triplenegative breast cancer: risk factors to potential targets. Clin Cancer Res 2008;14(24):8010-8018.

12. Carey LA, Perou CA, Livasy CA, Dressler LG, et al. Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.

13. Rakha EA, El-Rehim DA, Paish C, Green AR, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006;42:3149-3156.

14. Collett K, Stefansson IM, Eide J, Braaten A, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005;14:1108-1112.

15. Seewaldt VL, Scott V. Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med 2007;356:e12.

16. Kim MJ, Ro JY, Ahn SH, Kim HH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol 2006;37:1217- 1226.

17. Yang XR, Sherman ME, Rimm DL, Lissowska J, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-443.

18. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Brandao DF, et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005;47:458-466.

19. Potemski P, Kusinska R, Watala C, Plucienik E, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 2005;69:478-485.

20. Livasy CA, Karaca G, Nonda R, Tretiakova MS, et al. Phenotypic evaluation of basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:347-353.

21. Nielsen TO, Hsu FD, Jensen K, Cheang M, et al. Immunohistochemical and clinical characterization of the basal-like sybtype of invasive breast carcinoma. Clin Cancer Res 2004;10(16):5367-5374.

22. Rakha EA, El-Sayed ME, Green AR, Paish EC, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007;50:434-438.

23. Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation? Immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 2005;29:347-353.

24. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5 and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;447(4):688-694.

25. Livasy CA, Perou CM, Karaca G, Cowan DW, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007;38(2):197-204.

26. Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma. A phenotypically distinct entity. Arch Pathol Lab Med 2010;134:130-133.

27. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistological profile. Mod Pathol 2006;19(1):1506-1511.

28. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009;117(2):273-280.

29. Rodriguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G, Sarrió D, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene aplification study. Am J Surg Pathol 2007;31:501-508.

30. Vincent-Salomon A, Gruel L, Lucchesi C, MacGrogan G, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007;9:R24.

31. Koenig C, Dadmanesh F, Bratthauer G, Tavassoli F. Carcinoma arising in microglandular adenosis: an immunohistochemical analysis of 20 intraepithelial and invasive neoplasms. Int J Surg Pathol 2000;8:303-315.

32. Calza S, Hall P, Auer G, Bjöhle J, et al. Intrinsec molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006;8:R34.

33. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671.

34. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, et al. Morphological and immunophenotypical analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.

35. van de Rijn M, Perou CM, Tibshirani R, Haas P, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996.

36. Jones C, Ford E, Gillet C, Ryder K, et al. Molecular cytogenetic identification of subgroups of grade 3 invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004;10:5988-5997.

37. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998;433:119-129.

38. Rouzier R, Perou CM, Symmans WF, Ibrahim N, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.

39. Sorlie T, Perou CM, Fan C, Geisler S, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advances breast cancer. Mol Cancer Ther 2006;5:2914-2918.